

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Asymchem Laboratories (Tianjin) Co., Ltd.
凱萊英醫藥集團(天津)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6821)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the announcements of Asymchem Laboratories (Tianjin) Co., Ltd. (the “**Company**”) dated 19 December 2025 and 13 March 2026; and Next Day Disclosure Return dated 26 January 2026, respectively, in relation to, among others, (i) repurchase and cancellation of part of restricted A shares granted under the 2025 A share restricted share incentive scheme of the Company (the “**2025 A Share Scheme**”) (the “**Repurchase and Cancellation**”), and (ii) issue and allotment of new Shares to the trustee pursuant to the H share restricted share scheme of the Company (the “**Issuance and Allotment**”). In view of the changes of the registered capital of the Company as a result of the Repurchase and Cancellation and the Issuance and Allotment, the board of directors (the “**Board**”) of the Company has proposed the following amendments to the articles of association of the Company (the “**Proposed Amendments**”):

Before the amendment	After the amendment
Article 6 The registered capital of the Company is RMB 360,593,720 . The Company is a joint stock limited company with perpetual existence.	Article 6 The registered capital of the Company is RMB 360,780,970 . The Company is a joint stock limited company with perpetual existence.
Article 21 After the incorporation, the Company issued 22,863,500 domestic shares to domestic investors and other qualified investors for initial public offering upon approval of CSRC. After the abovementioned issuance, the total number of shares of the Company was 112,863,500, all being RMB ordinary shares. The Company issued 19,680,900 H shares to overseas investors for initial public offering upon approval of CSRC in 2021. After the abovementioned issuance, the total number of shares of the Company is 264,281,818, all being ordinary shares.	Article 21 After the incorporation, the Company issued 22,863,500 domestic shares to domestic investors and other qualified investors for initial public offering upon approval of CSRC. After the abovementioned issuance, the total number of shares of the Company was 112,863,500, all being RMB ordinary shares. The Company issued 19,680,900 H shares to overseas investors for initial public offering upon approval of CSRC in 2021. After the abovementioned issuance, the total number of shares of the Company is 264,281,818, all being ordinary shares.

Before the amendment	After the amendment
<p>The latest share capital structure of the Company is as follows: 360,593,720 ordinary shares, including 333,040,460 shares of domestically listed domestic shares (A shares), accounting for 92.36% of the total share capital of the Company; 27,553,260 shares of overseas-listed foreign shares (H shares), accounting for 7.64% of the total share capital of the Company.</p>	<p>The latest share capital structure of the Company is as follows: 360,780,970 ordinary shares, including 332,946,460 shares of domestically listed domestic shares (A shares), accounting for 92.28% of the total share capital of the Company; 27,834,510 shares of overseas-listed foreign shares (H shares), accounting for 7.72% of the total share capital of the Company.</p>

Except for the Proposed Amendments mentioned above, other provisions of the articles of association of the Company remain unchanged. The Proposed Amendments are prepared in Chinese language. In the event of any discrepancy between the English translation and the Chinese version, the Chinese version shall prevail.

General

The Proposed Amendments are subject to the approval by the shareholders of the Company (the “Shareholders”) by way of special resolutions, and will become effective upon such approval, provided that the Proposal on the Repurchase and Cancellation of Part of Restricted A Shares Granted under the 2025 A Share Scheme, as submitted by the Board to the general meeting for consideration, is approved. A circular containing, among others, details of the aforementioned issues will be published on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.asymchem.com) and despatched to the Shareholders (if necessary) as soon as possible.

The announcement is made in Chinese with an English translation. In case of any discrepancies, the Chinese version shall prevail.

By order of the Board
Asymchem Laboratories (Tianjin) Co., Ltd.
Dr. Hao Hong
*Chairperson of the Board, Executive Director
and Chief Executive Officer*

Tianjin, the PRC, 13 March 2026

As of the date of this announcement, the Board of Directors of the Company comprises Dr. Hao Hong as the Chairperson of the Board and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Dr. Sun Xuejiao, Dr. Hou Xinyi and Mr. Xie Weikai as independent non-executive Directors.